Teitel J - Search Results

1

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.

Vézina C, Carcao M, Infante-Rivard C, Lillicrap D, Stain AM, Paradis E, Teitel J, Rivard GE; Association of Hemophilia Clinic Directors of Canada and of the Canadian Association of Nurses in Hemophilia Care. Vézina C, et al. Among authors: teitel j. Haemophilia. 2014 Nov;20(6):771-6. doi: 10.1111/hae.12479. Epub 2014 Jul 17. Haemophilia. 2014. PMID: 25039669

2

Characterization of the original Christmas disease mutation (cysteine 206----serine): from clinical recognition to molecular pathogenesis.

Taylor SA, Duffin J, Cameron C, Teitel J, Garvey B, Lillicrap DP. Taylor SA, et al. Among authors: teitel j. Thromb Haemost. 1992 Jan 23;67(1):63-5. Thromb Haemost. 1992. PMID: 1615485

3

Carrier detection of haemophilia A using DNA markers in families with an isolated affected male.

Grover H, Phillips MA, Lillicrap DP, Giles AR, Garvey MB, Teitel J, Rivard G, Blanchette V, White BN, Holden JJ. Grover H, et al. Among authors: teitel j. Clin Genet. 1987 Jul;32(1):10-9. doi: 10.1111/j.1399-0004.1987.tb03316.x. Clin Genet. 1987. PMID: 2887317

4

A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.

Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. Giles AR, et al. Among authors: teitel j. Thromb Haemost. 1998 Apr;79(4):872-5. Thromb Haemost. 1998. PMID: 9569207

5

National haemophilia treatment protocols: Canada.

Teitel JM. Teitel JM. Haemophilia. 1998 Jul;4(4):422-3. doi: 10.1046/j.1365-2516.1998.4404212.x. Haemophilia. 1998. PMID: 9873766 No abstract available.

6

Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada.

Teitel JM, Card R, Strawczynski H. Teitel JM, et al. Haemophilia. 1998 Sep;4(5):731-8. doi: 10.1046/j.1365-2516.1998.00182.x. Haemophilia. 1998. PMID: 9873879

7

Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.

Giles AR, Rivard GE, Teitel J, Walker I. Giles AR, et al. Among authors: teitel j. Transfus Sci. 1998 Jun;19(2):139-48. doi: 10.1016/s0955-3886(98)00024-1. Transfus Sci. 1998. PMID: 10187039

8

The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada.

Chang H, Sher GD, Blanchette VS, Teitel JM. Chang H, et al. Among authors: teitel jm. Haemophilia. 1999 Jul;5(4):247-52. doi: 10.1046/j.1365-2516.1999.00321.x. Haemophilia. 1999. PMID: 10469178

9

Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations.

Teitel JM. Teitel JM. Haemophilia. 1999 Sep;5 Suppl 3:43-9. doi: 10.1046/j.1365-2516.1999.00037.x. Haemophilia. 1999. PMID: 10597387 Review. No abstract available.

10

Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A.

Lee DH, Walker IR, Teitel J, Poon MC, Ritchie B, Akabutu J, Sinclair GD, Pai M, Wu JW, Reddy S, Carter C, Growe G, Lillicrap D, Lam M, Blajchman MA. Lee DH, et al. Among authors: teitel j. Thromb Haemost. 2000 Mar;83(3):387-91. Thromb Haemost. 2000. PMID: 10744141

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters